Navigation Links
Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007
Date:2/13/2008

between $1.64 and $1.72, based on approximately 56 million

fully diluted shares outstanding for the year and a tax rate of 35%.

Recent Events

-- PROCLEIX ULTRIO Post-Marketing Study. Gen-Probe believes the Company

has met its goal of identifying a second case of hepatitis B "yield"

in the post-marketing study for the PROCLEIX ULTRIO assay. Yield is

defined as an HBV-infected blood donation that was intercepted by the

PROCLEIX ULTRIO assay, but that was initially negative based on

traditional serology tests. To date, participating blood banks have

screened approximately 500,000 blood donations in the study. The FDA

has approved the PROCLEIX ULTRIO assay to screen donated blood for

HIV-1 and hepatitis C virus (HCV), but not to screen for HBV, as the

initial clinical studies were not designed to, and did not,

demonstrate HBV yield. Within a month, Gen-Probe intends to submit a

supplemental Biologics License Application (BLA) to the US Food and

Drug Administration in hopes of gaining a donor screening claim for

HBV.

-- Carl Hull Named President and COO. On February 11, Gen-Probe

announced that Carl Hull was named the Company's president and chief

operating officer, effective March 1, 2008. Mr. Hull joined Gen-Probe

in February of 2007 as executive vice president and chief operating

officer. He oversees the Company's major operating functions,

including research and development, manufacturing, and sales and

marketing.

-- New Operations Executive. On November 19, Gen-Probe announced that

Jorgine Ellerbrock joined the Company as senior vice president,

operations. She joined the Company from Invitrogen Corporation, where

she had been vice president, operations, since 2004, most recently for

the Molecul
'/>"/>

SOURCE Gen-Probe Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Carl Hull Named President and Chief Operating Officer of Gen-Probe
2. Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2007 Earnings Conference Call
3. Gen-Probe to Webcast Three Upcoming Presentations
4. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
5. Gen-Probe to Webcast Presentation at Bank of Americas 37th Annual Investment Conference
6. Imagenetix Inc. Reports Third Fiscal Quarter Results
7. China-Biotics, Inc. Reports Third Quarter 2008 Financial Results
8. Maxygen Reports Fourth Quarter and Year End 2007 Financial Results
9. Cynosure Reports Record Revenues and Net Income for the Fourth Quarter of 2007
10. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
11. Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... (PRWEB) September 30, 2014 On September 11, ... James Sherley in anticipation of a session that he will ... Toxicology Summit,” scheduled for February 17-18, 2015 in London. ... Pharma IQ asked Dr. Sherley to respond to several questions ... toxicity, challenges to evaluating stem cell toxicity, and future trends ...
(Date:9/29/2014)... CA (PRWEB) September 30, 2014 ... million burn injuries require medical attention. In the ... brings serious complications to battlefield medical care. More ... Iraq and Afghanistan. Burn wounds heal slowly, remain ... can be excessive, physically debilitating and functionally damaging. ...
(Date:9/29/2014)... TORONTO , Sept. 29, 2014 /PRNewswire/ - Portage Biotech ... Exchange: PBT.U), is pleased to announce that its three ... of Portage, who advanced $ 100,000 each in July ... have their Notes and related Coupons converted into 3,500,001 ... and carried 5% coupon. Both the Note and the ...
(Date:9/29/2014)... 29, 2014 Transparency Market Research, in ... SPPS, LPPS, HPPS, by Application - Cancer, Metabolic, CVS, ... and by Delivery) - Global Industry Analysis, Size, Share, ... the global peptide therapeutics market was worth US$14.1 billion ... by 2018 at an 8.7% CAGR. , The two ...
Breaking Biology Technology:Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 2Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 3Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 4Faster Healing with Fewer Scars 2Portage announces conversion of its debt into equity 2Portage announces conversion of its debt into equity 3Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 2Global Peptide Therapeutics Market to be Worth US$25.4 Billion by 2018: Transparency Market Research 3
... Sequella, Inc., a clinical-stage biopharmaceutical company focused on ... today announced that it received a $594,661 two-year ... National Institutes of Health (NIH), National Institute of ... of SQ641, Sequella,s lead compound in its capuramycin ...
... Dr. Michael Merzenich , PhD - ... plasticity expert and tech entrepreneur - was formally ... D.C. Also a member of the National Academy of Sciences, ... and doctors in the U.S. who have been selected for ...
... CITY, England, October 12 , ... and Milestones Plus,Royalties , Heptares Therapeutics ... announced today that it has,entered into an option agreement with ... StaR(TM) technology to generate novel,drug leads against a nominated, unspecified ...
Cached Biology Technology:Sequella Obtains Funding to Continue Expansion of its Anti-infectives Pipeline 2Sequella Obtains Funding to Continue Expansion of its Anti-infectives Pipeline 3Dr. Michael Merzenich Joins Venerable Short List Honored for Cutting-Edge Neuroscientific Research 2Dr. Michael Merzenich Joins Venerable Short List Honored for Cutting-Edge Neuroscientific Research 3Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target 2Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target 3
(Date:9/30/2014)... National Institutes of Health (NIH) awarded Lawrence Livermore ... an electrode array system that will enable researchers ... unprecedented resolution and scale. , LLNL,s grant-funded project ... Obama,s BRAIN (Brain Research through Advancing Innovative ... revolutionize our understanding of the human mind and ...
(Date:9/30/2014)... professor and Howard Hughes Medical Institute investigator, and ... recipients in the 2014 round of grants from ... BRAIN (Brain Research through Advancing Innovative Neurotechnologies) Initiative ... September 30, provides more than $3 million in ... , The BRAIN Initiative, launched last year, is ...
(Date:9/30/2014)... of environmental scientists and engineers, led by Clemson ... three-year, $5.25 million grant from the U.S. Department ... to make a direct positive impact on South ... disposal of radioactive contaminants. , "Understanding the scientific ... with environmental aspects of nuclear technologies is imperative ...
Breaking Biology News(10 mins):NIH taps lab to develop sophisticated electrode array system to monitor brain act 2NIH taps lab to develop sophisticated electrode array system to monitor brain act 3Salk scientists receive $3 million for BRAIN Initiative grant 2Researchers get $5.25 million to advance nuclear technologies in South Carolina 2
... produce increases, vegetable and fruit producers are facing ... challenged to examine traditional production practices in order ... A recent focus on both the positive and ... the globe working to find methods that can ...
... Motor commands issued by the brain to activate arm ... led by Professor Silvia Arber at the University of ... Research has now discovered, many neurons in the spinal ... but at the same time also back to the ...
... Drosophila (fruit fly) can be synchronised using vibrations, ... . The results suggest that an animal,s own movements can ... daily rhythms characterising most of our bodily functions including the ... and temperature. Researchers at UCL and Queen Mary, University ...
Cached Biology News:Nitrogen management studied in greenhouse pepper production 2Cc to the brain: How neurons control fine motor behavior of the arm 2Cc to the brain: How neurons control fine motor behavior of the arm 3
... The Zero Blunt TOPO ... Sequencing is designed for ... of blunt-end PCR products. ... 5-minute TOPO Cloning and ...
... Blunt TOPO PCR Cloning ... designed for cloning and ... PCR products. The pCR4Blunt-TOPO ... Cloning and greater than ...
... EA. Ultrospec 6300 pro UV/Visible ... the Pharmacopoeia in terms of instrument specification ... being able to be used for rapid, ... excellent scanning capability., *Press to read high ...
...
Biology Products: